Skip to main content
Premium Trial:

Request an Annual Quote

CyVek Nets $2M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life science technologies start-up CyVek has netted almost $2 million through a private equity offering, according to a filing with the US Securities and Exchange Commission.

The firm is based in Wallingford, Conn.

According to a profile for CyVek CEO and President Per Hellsund on the networking website LinkedIn, the company's technology will be used in clinical diagnostic settings, and it is based on a novel microfluidic test cartridge that may be coupled with a multiplex system.

According to the SEC filing, the $1.95 million in funding came from five investors. The company did not state in the filing how the funding will be used.

Hellsund formerly was president of inc.jet Inc. and he was VP of operations at Gunther International.

In addition, listed as an executive officer and director of the firm is Kevin Didden, the president and CEO of process monitoring technologies firm CiDRA and former chairman of CyVera, the digital microbead technology developer that was acquired in 2004 by Illumina. That technology has since been launched by Illumina under the BeadXpress name.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.